Morgan Stanley started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $25.00 price objective on the stock.
Separately, Stifel Nicolaus assumed coverage on shares of Contineum Therapeutics in a research report on Tuesday. They set a buy rating and a $29.00 price target on the stock.
Read Our Latest Research Report on CTNM
Contineum Therapeutics Trading Down 2.5 %
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Further Reading
- Five stocks we like better than Contineum Therapeutics
- Investing in Construction Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- The Role Economic Reports Play in a Successful Investment Strategy
- Hilton Demonstrates Asset Light is Right for Investors
- How to Use the MarketBeat Stock Screener
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.